These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 26466856)

  • 21. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.
    Ko S; Park S; Sohn MH; Jo M; Ko BJ; Na JH; Yoo H; Jeong AL; Ha K; Woo JR; Lim C; Shin JH; Lee D; Choi SY; Jung ST
    Exp Mol Med; 2022 Nov; 54(11):1850-1861. PubMed ID: 36319752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human FcRn Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies.
    Roopenian DC; Christianson GJ; Proetzel G; Sproule TJ
    Methods Mol Biol; 2016; 1438():103-14. PubMed ID: 27150086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
    Kelton W; Mehta N; Charab W; Lee J; Lee CH; Kojima T; Kang TH; Georgiou G
    Chem Biol; 2014 Dec; 21(12):1603-9. PubMed ID: 25500223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway.
    Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM
    J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.
    Gurbaxani B; Dela Cruz LL; Chintalacharuvu K; Morrison SL
    Mol Immunol; 2006 Mar; 43(9):1462-73. PubMed ID: 16139891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Humanized Mouse Model to Study Human Albumin and Albumin Conjugates Pharmacokinetics.
    Low BE; Wiles MV
    Methods Mol Biol; 2016; 1438():115-22. PubMed ID: 27150087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement.
    Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA
    J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity.
    Mandrup OA; Ong SC; Lykkemark S; Dinesen A; Rudnik-Jansen I; Dagnæs-Hansen NF; Andersen JT; Alvarez-Vallina L; Howard KA
    Commun Biol; 2021 Mar; 4(1):310. PubMed ID: 33686177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FcRn: the neonatal Fc receptor comes of age.
    Roopenian DC; Akilesh S
    Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
    Andersen JT; Dee Qian J; Sandlie I
    Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.
    Andersen JT; Daba MB; Berntzen G; Michaelsen TE; Sandlie I
    J Biol Chem; 2010 Feb; 285(7):4826-36. PubMed ID: 20018855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
    Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
    Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
    [No Abstract]   [Full Text] [Related]  

  • 37. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.
    Tam SH; McCarthy SG; Brosnan K; Goldberg KM; Scallon BJ
    MAbs; 2013; 5(3):397-405. PubMed ID: 23549129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.
    Roopenian DC; Christianson GJ; Sproule TJ; Brown AC; Akilesh S; Jung N; Petkova S; Avanessian L; Choi EY; Shaffer DJ; Eden PA; Anderson CL
    J Immunol; 2003 Apr; 170(7):3528-33. PubMed ID: 12646614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants.
    Petersen SS; Kläning E; Ebbesen MF; Andersen B; Cameron J; Sørensen ES; Howard KA
    Mol Pharm; 2016 Feb; 13(2):677-82. PubMed ID: 26654692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor.
    Seijsing J; Yu S; Frejd FY; Höiden-Guthenberg I; Gräslund T
    Sci Rep; 2018 Mar; 8(1):5141. PubMed ID: 29572538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.